OpenBilldrug price receipt

NADAC week of 2026-10-14

GVOKE 1 MG/0.2 ML KIT

FDA nonproprietary name: glucagon injection, solution

For 0.2 mL

Pharmacies pay

$320.20 filed

0.2 × $1,600.98636 per ML

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D paid

$305.03 filed

0.2 × $1,525.1287 per ML, Part D average

Medicare's price is not your price.

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18


The spread

0.95× estimated

Medicare paid about what pharmacies pay.

Part D averages every strength and form sold under “Gvoke” / “Glucagon” into one figure, so it is not specific to this NDC.

OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)

Cost-plus estimate

$373.23 estimated

$320.20 + $48.03 (15%) + $5.00 fee per fill = $373.23

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

GVOKE 1 MG/0.2 ML KIT is how the CMS NADAC file names this product. The FDA NDC Directory lists it as glucagon injection, solution, under the trade name “Gvoke Kit”.

FDA gives its dosage form as injection, solution and its route as subcutaneous.

The labeler, the company named on the label, is Xeris Pharmaceuticals, Inc.

FDA lists it under 2 Established Pharmacologic Classes: Antihypoglycemic Agent and Gastrointestinal Motility Inhibitor.

The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 72065-0140-11.

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $320.20 for 0.2 mL (0.2 × $1,600.98636 per ML, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation codes for it: 1, calculated from the most recently completed pharmacy survey; 5, calculated based on package size.

The NDC

Other strengths, forms and brands

5 other products in the NADAC file share the FDA nonproprietary name glucagon injection, solution with GVOKE 1 MG/0.2 ML KIT.

ProductPharmacies pay per unitMedicare per unit
GVOKE 1 MG/0.2 ML KIT this page
brand · injection, solution
$1,600.98636 per ML filed
eff. 2026-09-23
$1,525.1287 per ML filed
Part D 2024 average
GVOKE HYPOPEN 1-PK 1 MG/0.2 ML
brand · injection, solution
$1,603.18226 per ML filed
eff. 2026-09-23
We don’t know yet
GVOKE HYPOPEN 2-PK 1 MG/0.2 ML
brand · injection, solution
$1,596.19346 per ML filed
eff. 2026-09-23
We don’t know yet
GVOKE HYPOPEN 2PK 0.5 MG/0.1 ML
brand · injection, solution
$3,202.32985 per ML filed
eff. 2026-09-23
We don’t know yet
GVOKE PFS 1-PK 1 MG/0.2 ML SYR
brand · injection, solution
$1,600.95652 per ML filed
eff. 2026-09-23
We don’t know yet
GVOKE PFS 2-PK 1 MG/0.2 ML SYR
brand · injection, solution
$1,604.33929 per ML filed
eff. 2026-09-23
We don’t know yet

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

Its NADAC price is $1,600.98636 per ML filed.

Of the 7 other products in FDA’s Antihypoglycemic Agent class priced per ML, 3 have a higher middle NADAC price and 4 a lower one. The one in the middle is GVOKE PFS 1-PK 1 MG/0.2 ML SYR, at $1,600.95652 per ML filed (eff. 2026-09-23).

Of the 5 other products in FDA’s Gastrointestinal Motility Inhibitor class priced per ML, 3 have a higher middle NADAC price and 2 a lower one. The one in the middle is GVOKE HYPOPEN 1-PK 1 MG/0.2 ML, at $1,603.18226 per ML filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

What Medicare paid

Medicare Part D paid $305.03 for 0.2 mL, at an average of $1,525.1287 per ML in 2024 (2024-01-01 to 2024-12-31) for “Gvoke” and “Glucagon”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 2,163 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

Questions

Why is the comparison with Medicare for GVOKE 1 MG/0.2 ML KIT labelled estimated?
Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Gvoke / Glucagon: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's ML. Joined on brand name.
Why does this page start at 0.2 mL?
NADAC prices this product per ML. The FDA NDC Directory’s package description gives 0.2 mL in one package for this product’s NDC (“.2 mL in 1 CARTON (72065-140-11)”), so the card starts at one package: 0.2 ML. Change it to match your prescription.